Reyon Pharmaceutical Co Ltd Total Liabilities
Reyon Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Reyon Pharmaceutical Co Ltd (102460) has total liabilities worth ₩239.99 Billion KRW (≈ $162.63 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 102460 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Reyon Pharmaceutical Co Ltd (2008–2024)
Total liabilities of Reyon Pharmaceutical Co Ltd from 2008 to 2024. This chart illustrates how Reyon Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Reyon Pharmaceutical Co Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
Reyon Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Reyon Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kulmbacher Brauerei Aktien-Gesellschaft
MU:KUL
|
Germany | €168.79 Million |
|
Gladiator Metals Corp
V:GLAD
|
Canada | CA$7.62 Million |
|
RiverNorth Managed Duration Municipal Income Fund II Inc.
NYSE:RMMZ
|
USA | $95.41 Million |
|
Dongsung Corporation
KO:102260
|
Korea | ₩506.98 Billion |
|
Willbes
KO:008600
|
Korea | ₩199.46 Billion |
|
Arsan Tekstil Ticaret ve Sanayi AS
IS:ARSAN
|
Turkey | TL3.36 Billion |
|
Creative Newtech Limited
NSE:CREATIVE
|
India | Rs4.47 Billion |
|
Ilshinstone
KO:007110
|
Korea | ₩33.23 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down Reyon Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Reyon Pharmaceutical Co Ltd total assets.
Liquidity & Leverage Metrics
Reyon Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Reyon Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Reyon Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Reyon Pharmaceutical Co Ltd (2008–2024)
The table below shows the annual total liabilities of Reyon Pharmaceutical Co Ltd from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩250.05 Billion ≈ $169.46 Million |
-0.44% |
| 2023-12-31 | ₩251.15 Billion ≈ $170.20 Million |
+6.00% |
| 2022-12-31 | ₩236.93 Billion ≈ $160.56 Million |
+1.80% |
| 2021-12-31 | ₩232.74 Billion ≈ $157.73 Million |
+165.93% |
| 2020-12-31 | ₩87.52 Billion ≈ $59.31 Million |
+67.69% |
| 2019-12-31 | ₩52.19 Billion ≈ $35.37 Million |
-32.90% |
| 2018-12-31 | ₩77.77 Billion ≈ $52.71 Million |
+9.27% |
| 2017-12-31 | ₩71.18 Billion ≈ $48.24 Million |
+133.83% |
| 2016-12-31 | ₩30.44 Billion ≈ $20.63 Million |
-0.42% |
| 2012-12-31 | ₩30.57 Billion ≈ $20.72 Million |
+6.39% |
| 2011-12-31 | ₩28.73 Billion ≈ $19.47 Million |
+29.70% |
| 2009-12-31 | ₩22.15 Billion ≈ $15.01 Million |
-2.14% |
| 2008-12-31 | ₩22.64 Billion ≈ $15.34 Million |
-- |
About Reyon Pharmaceutical Co Ltd
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough … Read more